Latest Media Releases

All A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

BARD1 Life Sciences - Notification of cessation of securities (ASX:IIQ)

To view the Notification of cessation of +securities, download the attached PDF.

BARD1 Life Sciences - Appendix 4E and Preliminary Financial Report (ASX:IIQ)

To view the appendix, download the attached PDF.

BARD1 Life Sciences - Change in substantial holding (ASX:IIQ)

To view the Notice of change of interests of substantial holder, download the attached PDF.

BARD1 Life Sciences - Change of Director's Interest - Powell (ASX:IIQ)

To view the notice, download the attached PDF.

BARD1 Life Sciences - Change of Director's Interest - Dr Geoffrey Cumming (ASX:IIQ)

To view the notice, download the attached PDF.

BARD1 Life Sciences - Change of Director's Interest - Johnston (ASX:IIQ)

To view the notice, download the attached PDF.

BARD1 Life Sciences - Appendix 2A (ASX:IIQ)

To view the Application for quotation of +securities, download the attached PDF.

BARD1 Life Sciences Share Purchase Plan Completed Oversubscribed (ASX:IIQ)

SPP successfully completed with oversubscribed applications of $3.4m accepted Total capital raised of $18.4m under both the SPP and recent placement to institutional and sophisticated investors ...read more

BARD1 Life Sciences - Proof-of-Concept for SubB2M ELISA-Based Ovarian Cancer Test (ASX:IIQ)

-- POC achieved in feasibility studies demonstrating that a SubB2M/CA125 ELISA can detect the CA125 biomarker for ovarian cancer in patient samples -- SubB2M/CA125 ELISA-based test detects CA125-...read more

BARD1 Life Sciences lodges SPP and options prospectus (ASX:IIQ)

BARD1 Life Sciences Limited (ASX:BD1) (BARD1 or the Company) is pleased to announce that following the successful completion and issue of placement shares to sophisticated, institutional and profess...read more

BARD1 Life Sciences - Appendix 4C & Quarterly Activities Report (ASX:IIQ)

Strong commercial progress: -- hTERT receipts of $184k for the period compared to previous quarter of $42k -- RUO1 EXO-NET® launched and exosome capture data presented at ISEV2021 in May 2021...read more

BARD1 Life Sciences - Appendix 2A (ASX:IIQ)

To view the Application for quotation of +securities, download the attached PDF.

BARD1 Life Sciences Collaborator Uni of QLD Announces Ovarian Cancer Data (ASX:IIQ)

-- University of Queensland researchers have unveiled promising results for a potential exosome-based blood test for ovarian cancer -- BARD1’s RUO EXO-NET® product has been used by the re...read more

BARD1 Life Sciences - Updated Investor Presentation (ASX:IIQ)

To view the presentation, download the attached PDF.

BARD1 Life Sciences - Terms of issue of Options (ASX:IIQ)

Rights and liabilities attaching to the Options Unless otherwise defined, capitalised terms used below have the meaning given to those terms in the Appendix 3B announced to the market on 23 July ...read more

Viewing: 91 - 105 of 111 Previous | Next